Tablets Capsules

TC0620

Issue link: https://www.e-digitaleditions.com/i/1257854

Contents of this Issue

Navigation

Page 51 of 67

50 | Solid Dosage Sourcebook 2020 The company Syntegon Pharma Technology, formerly Bosch Packaging Tech- nology, is one of the leading providers of process technology and packaging solutions for the pharmaceutical industry all over the world. Backed by decades of experience, Syntegon has devel- oped a comprehensive portfolio for the pharmaceutical industry. The portfolio The portfolio ranges from single units to complete lines and inte- grated systems, and includes process technology, primary and second- ary packaging as well as handling and inspection technology. Syn- tegon offers software solutions for track and trace and Industry 4.0 applications, qualification and vali- dation support, as well as technical customer services to optimize opera- tional performance. Excellence in solid dosage Syntegon not only specializes in production-size fluid bed systems, high-shear mixers, coaters, tablet presses and capsule filling machines. The portfolio for solid dosage forms also includes several laboratory devices as well as support in formu- lation development and scale-up from laboratory to production scale. Capsule and tablet containment • The GKF 720 capsule filling machine processes powders, pel- lets and tablets in small batches for R&D or clinical purposes, ensuring highest protection for operator, machine and product up to OEB 5 product requirements. • The TPR 200 tablet press is also suited for containment appli- cations. It is ideal for small to medium batches with outputs of more than 230,000 tab- lets per hour. Its hygienic, easy- to-clean design enables fast product changeovers. Continuous manufacturing • Thanks to a unique and proven technology from the Syntegon subsidiary Hüttlin, the Xelum pro- duction platform doses even the smallest amounts of active ingre- dients precisely. With the X-key approach, active ingredients and excipients are dosed as discrete masses and not as continual mass flow. They continuously run through the process chain and are removed successively. • The Xelum R&D also achieves optimum API dosage and faster time-to-market of new formula- tions. Time-consuming scale-up is not needed, since the laboratory device uses the same components as the Xelum production platform. Syntegon Pharma Technology 8700 Wyoming Ave N. Minneapolis, MN 55445 763-424-4700 pharma-na@syntegon.com www.syntegon.com Syntegon

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets Capsules - TC0620